279 related articles for article (PubMed ID: 28456096)
1. Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene.
Fairoozy RH; Cooper J; White J; Giambartolomei C; Folkersen L; Wannamethee SG; Jefferis BJ; Whincup P; Ben-Shlomo Y; Kumari M; Kivimaki M; Wong A; Hardy R; Kuh D; Gaunt TR; Casas JP; McLachlan S; Price JF; Hingorani A; Franco-Cereceda A; Grewal T; Kalea AZ; Humphries SE;
Atherosclerosis; 2017 Jun; 261():60-68. PubMed ID: 28456096
[TBL] [Abstract][Full Text] [Related]
2. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
Seidah NG; Poirier S; Denis M; Parker R; Miao B; Mapelli C; Prat A; Wassef H; Davignon J; Hajjar KA; Mayer G
PLoS One; 2012; 7(7):e41865. PubMed ID: 22848640
[TBL] [Abstract][Full Text] [Related]
3. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Mayer G; Poirier S; Seidah NG
J Biol Chem; 2008 Nov; 283(46):31791-801. PubMed ID: 18799458
[TBL] [Abstract][Full Text] [Related]
4. Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.
Ly K; Saavedra YG; Canuel M; Routhier S; Desjardins R; Hamelin J; Mayne J; Lazure C; Seidah NG; Day R
J Biol Chem; 2014 Jun; 289(25):17732-46. PubMed ID: 24808179
[TBL] [Abstract][Full Text] [Related]
5. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.
Hussain Y; Ding Q; Connelly PW; Brunt JH; Ban MR; McIntyre AD; Huff MW; Gros R; Hegele RA; Feldman RD
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):213-21. PubMed ID: 25395619
[TBL] [Abstract][Full Text] [Related]
6. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
[TBL] [Abstract][Full Text] [Related]
7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
8. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
Kotowski IK; Pertsemlidis A; Luke A; Cooper RS; Vega GL; Cohen JC; Hobbs HH
Am J Hum Genet; 2006 Mar; 78(3):410-22. PubMed ID: 16465619
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Polisecki E; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Blauw GJ; Westendorp RG; de Craen AJ; Trompet S; Buckley BM; Murphy MB; Ordovas JM; Schaefer EJ;
Atherosclerosis; 2008 Sep; 200(1):95-101. PubMed ID: 18262190
[TBL] [Abstract][Full Text] [Related]
11. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Functional Variant(s) that Explain the Low-Density Lipoprotein Receptor (LDLR) GWAS SNP rs6511720 Association with Lower LDL-C and Risk of CHD.
Fairoozy RH; White J; Palmen J; Kalea AZ; Humphries SE
PLoS One; 2016; 11(12):e0167676. PubMed ID: 27973560
[TBL] [Abstract][Full Text] [Related]
13. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Cohen JC; Boerwinkle E; Mosley TH; Hobbs HH
N Engl J Med; 2006 Mar; 354(12):1264-72. PubMed ID: 16554528
[TBL] [Abstract][Full Text] [Related]
14. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
Pedro-Botet J; Badimón L
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
[TBL] [Abstract][Full Text] [Related]
15. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
Chernogubova E; Strawbridge R; Mahdessian H; Mälarstig A; Krapivner S; Gigante B; Hellénius ML; de Faire U; Franco-Cereceda A; Syvänen AC; Troutt JS; Konrad RJ; Eriksson P; Hamsten A; van 't Hooft FM
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1526-34. PubMed ID: 22460556
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
Picard C; Poirier A; Bélanger S; Labonté A; Auld D; Poirier J;
PLoS One; 2019; 14(8):e0220254. PubMed ID: 31437157
[TBL] [Abstract][Full Text] [Related]
18. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of PCSK9: its role in LDL metabolism.
Horton JD; Cohen JC; Hobbs HH
Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
